Newsroom

Media coverage - Stockhead

WATCH: Our CEO Dr David Atkins discusses Rhythm's mission to make cancer more treatable through earlier detection on the latest episode of Long Shortz from Stockhead.

In this interview with Tylah Tully, Dr Atkins explains how we're transforming bowel cancer screening with ColoSTAT®, our groundbreaking blood-based diagnostic test designed to be more accessible and effective than current stool-based methods.

Key discussion points include:
- Our mission to detect cancer earlier when it's most treatable
- How ColoSTAT® offers a simpler alternative for patients
- Recent redevelopment achievements
- The potential impact on bowel cancer detection in Australia and beyond

With bowel cancer being Australia's second-biggest cancer killer, accessible screening solutions like ColoSTAT® could be game-changing for patient outcomes.

Watch the full chat here: https://tinyurl.com/5aahkkb3

Stockhead highlights ColoSTAT® verification milestone

Stockhead's special report covers Rhythm's successful completion of verification and validation of our second-generation ColoSTAT® Beta assay kits. The article emphasises how our blood-based bowel cancer test is now "optimised for routine lab use" with significant improvements in turnaround times and performance.

As CEO Dr David Atkins notes in the piece: "This is the first time the company has had a truly stable and reliable, simple to use ColoSTAT® assay with demonstrated performance."

The piece details our 96% success rate across 23,000 data points and explains how ColoSTAT® offers a minimally invasive alternative for patients "currently unwilling or unable to use traditional screening methods" for bowel cancer detection.

Read the article here: https://tinyurl.com/bdnw2ncj

Media coverage - Business News Australia

Rhythm announced it was acquiring the Genetype business and assets to create a diversified oncology business with significant growth potential. The Genetype business is a world leader in genetic-integrated risk assessment that offers population level predictive risk testing for a range of cancers and other serious and common diseases. The ability to quantify risk of disease using polygenic risk scores and clinical factors supports Rhythm's goal of detecting disease earlier in a uniquely personal manner.

Read the news coverage here: https://tinyurl.com/mrs4chw2

Media coverage - Stockhead

Rhythm announced to the market that we had attained all key milestones for 2024. Read the subsequent media coverage in Stockhead here: https://tinyurl.com/y7pbbr5r

Media coverage - Small Caps

We announced to the market that preliminary testing of 200 patient serum samples using the new multiplex Alpha antibody kit revealed superior analytical results compared to tests performed on the first-generation product. Read more here: https://tinyurl.com/5est5upc

Interview - MTPConnect Podcast

In June 2023, Rhythm Biosciences Chief Commercial Officer Elena Deak attended BIO in Boston where she spoke with Caroline Duell from MTPConnect.

"Back in June, MTPConnect joined the Australian delegation at BIO in Boston and organised several activities to showcase Australia’s fast-growing life sciences sector to the international biotech industry.

In part one of this BIO episode, host Caroline Duell heads to the Australian Pavilion at the Boston Convention Centre to catch up with Australian companies, entrepreneurs and researchers looking to do business at BIO and drive collaborations, partnerships and investments."

For more on MTP Connect and the podcast visit: https://www.mtpconnect.org.au/mtpconnectpodcast

Elena's Interview starts at 19:05. To listen, click play: